We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Molecular Assays Test for Human Papillomavirus

By LabMedica International staff writers
Posted on 19 Mar 2009
Two new molecular assays have been introduced in the United States for human papillomavirus (HPV) testing. More...
The high-risk (HR) test is designed to detect the 14 high-risk types of HPV known to cause cervical cancer, while the 16/18 assay is a test for genotyping HPV types 16 and 18, known to be associated with approximately 70% of all cervical cancers in the United States.

The US Food and Drug Administration (FDA; Rockville, MD, USA) has cleared for marketing Hologic's (Bedford, MA, USA) two assays, Cervista HPV high-risk (HR) and Cervista HPV 16/18, for HPV testing. This means that Hologic is the second firm to gain FDA clearance to sell a molecular diagnostic for the cervical cancer in the US.

The Cervista HPV HR test includes an internal control to verify adequate cellularity for testing, which should reduce the potential for false-negative results. The firm also noted that it requires a smaller specimen volume that may minimize inconclusive or indeterminate results, which may lead to fewer patients being called back for repeat testing. The HPV strains identified by the Cervista HPV-16/18 test represent the two most oncogenic and persistent types of HPV.

"We believe, while competition is increasing, the HPV marketplace is significantly large and underpenetrated, allowing for multiple players to be successful," wrote Peter Lawson, analyst at Thomas Weisel Partners (San Francisco, CA, USA), specialists in growth segments of the economy. "The US market is around 25 % penetrated, while penetration in Europe and Asia are in the single digits. The largest driver for the market could occur should the HPV test supplant the Pap as the primary screen, which could occur in smaller European countries in the near future, though widespread adoption is probably years away."

Related Links:

US Food and Drug Administration
Hologic
Thomas Weisel Partners



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.